Uveitis, Intermediate
Information
- Disease name
- Uveitis, Intermediate
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05953688 | Active, not recruiting | Phase 2 | POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU | June 14, 2023 | April 30, 2025 |
| NCT00404612 | Completed | Phase 3 | A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis | January 2007 | May 2009 |
| NCT00404742 | Completed | Phase 3 | A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis | January 2007 | May 2009 |
| NCT01092533 | Completed | Phase 3 | Myfortic for the Treatment of Non-infectious Intermediate Uveitis | March 2010 | October 2015 |
| NCT02049476 | Completed | Phase 4 | Study of the Effectiveness of Ozurdex for the Control of Uveitis | January 2014 | June 30, 2018 |
| NCT00344253 | Completed | Phase 3 | Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis | March 2006 | January 2012 |
| NCT02255032 | Completed | Phase 2 | Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis | October 2014 | January 2016 |
| NCT02595398 | Completed | Phase 3 | Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis | November 17, 2015 | January 18, 2018 |
| NCT02952001 | Completed | MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301 | December 13, 2017 | May 22, 2018 | |
| NCT03097315 | Completed | Phase 3 | Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis | April 4, 2017 | January 24, 2018 |
| NCT06431373 | Not yet recruiting | Phase 3 | A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) | August 23, 2024 | August 23, 2027 |
| NCT06085079 | Recruiting | Phase 4 | Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study | June 1, 2022 | December 30, 2024 |
| NCT05101928 | Recruiting | Phase 4 | Ozurdex Monotherapy Trial | November 30, 2021 | September 30, 2027 |
| NCT05486468 | Recruiting | Phase 3 | The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment | October 5, 2022 | December 2024 |
| NCT02125266 | Terminated | Phase 1/Phase 2 | Safety and Preliminary Efficacy Study of V404 PDS in Uveitis | April 2014 | March 2015 |
| NCT03656692 | Terminated | Phase 4 | Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) | October 5, 2018 | July 14, 2020 |
| NCT05070728 | Terminated | Phase 3 | Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) | November 17, 2021 | April 12, 2023 |
| NCT01905124 | Withdrawn | Phase 2 | Safety &Efficacy of CF101 to Subjects With Uveitis | January 2019 | October 2019 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D015867